Enhancing Oral Vaccine Potency by Targeting Intestinal M Cells
Tóm tắt
Từ khóa
Tài liệu tham khảo
JR McGhee, 1992, The mucosal immune system: from fundamental concepts to vaccine development., Vaccine, 10, 75, 10.1016/0264-410X(92)90021-B
JR McGhee, 1992, Mucosal immunity to vaccines: current concepts for vaccine development and immune response analysis., Adv Exp Med Biol, 327, 3, 10.1007/978-1-4615-3410-5_2
J Xu-Amano, 1992, Induction of T helper cells and cytokines for mucosal IgA responses., Adv Exp Med Biol, 327, 107, 10.1007/978-1-4615-3410-5_13
J Mestecky, 1987, The common mucosal immune system and current strategies for induction of immune responses in external secretions., J Clin Immunol, 7, 265, 10.1007/BF00915547
A Azizi, 2010, Mucosal HIV vaccines: a holy grail or a dud?, Vaccine, 28, 4015, 10.1016/j.vaccine.2010.04.018
EL Parr, 1990, A comparison of antibody titres in mouse uterine fluid after immunization by several routes, and the effect of the uterus on antibody titres in vaginal fluid., J Reprod Fertil, 89, 619, 10.1530/jrf.0.0890619
B Haneberg, 1994, Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina measured by a new method for collection of secretions from local mucosal surfaces., Infect Immun, 62, 15, 10.1128/IAI.62.1.15-23.1994
PA Kozlowski, 1997, Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women., Infect Immun, 65, 1387, 10.1128/IAI.65.4.1387-1394.1997
CL Sentman, 2004, Recruitment of uterine NK cells: induction of CXC chemokine ligands 10 and 11 in human endometrium by estradiol and progesterone., J Immunol, 173, 6760, 10.4049/jimmunol.173.11.6760
CR Wira, 2003, Oestradiol regulation of antigen presentation by uterine stromal cells: role of transforming growth factor-beta production by epithelial cells in mediating antigen-presenting cell function., Immunology, 109, 398, 10.1046/j.1365-2567.2003.01670.x
FX Lu, 1999, Immunoglobulin concentrations and antigen-specific antibody levels in cervicovaginal lavages of rhesus macaques are influenced by the stage of the menstrual cycle., Infect Immun, 67, 6321, 10.1128/IAI.67.12.6321-6328.1999
J Mestecky, 2005, Immunologic uniqueness of the genital tract: challenge for vaccine development., Am J Reprod Immunol, 53, 208, 10.1111/j.1600-0897.2005.00267.x
M Lagranderie, 1998, A cocktail of Mycobacterium bovis BCG recombinants expressing the SIV Nef, Env, and Gag antigens induces antibody and cytotoxic responses in mice vaccinated by different mucosal routes., AIDS Res Hum Retroviruses, 14, 1625, 10.1089/aid.1998.14.1625
C Bergquist, 1997, Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina., Infect Immun, 65, 2676, 10.1128/IAI.65.7.2676-2684.1997
Z Durrani, 1998, Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization., J Immunol Methods, 220, 93, 10.1016/S0022-1759(98)00145-8
Y Hirabayashi, 1990, Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination., Vaccine, 8, 243, 10.1016/0264-410X(90)90053-O
KM Narayan, 2010, Comparative efficacy of influenza vaccines., N Engl J Med, 362, 179, 10.1056/NEJMc0910674
AE Fiore, 2009, Seasonal influenza vaccines., Curr Top Microbiol Immunol, 333, 43
A Miyake, 2004, Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques., J Med Virol, 73, 368, 10.1002/jmv.20100
J Stowe, 2006, Bell's palsy and parenteral inactivated influenza vaccine., Hum Vaccin, 2, 110, 10.4161/hv.2790
DJ Lewis, 2009, Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin., PLoS ONE, 4, e6999, 10.1371/journal.pone.0006999
M Mutsch, 2004, Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland., N Engl J Med, 350, 896, 10.1056/NEJMoa030595
U Baumann, 2008, Mucosal vaccination against bacterial respiratory infections., Expert Rev Vaccines, 7, 1257, 10.1586/14760584.7.8.1257
CG Branger, 2009, Oral vaccination with LcrV from Yersinia pestis KIM delivered by live attenuated Salmonellaenterica serovar Typhimurium elicits a protective immune response against challenge with Yersinia pseudotuberculosis and Yersinia enterocolitica., Vaccine, 27, 5363, 10.1016/j.vaccine.2009.06.078
AR Fooks, 2000, Development of oral vaccines for human use., Curr Opin Mol Ther, 2, 80
A Kostrzak, 2009, Oral administration of low doses of plant-based HBsAg induced antigen-specific IgAs and IgGs in mice, without increasing levels of regulatory T cells., Vaccine, 27, 4798, 10.1016/j.vaccine.2009.05.092
D Grdic, 1999, The mucosal adjuvant effects of cholera toxin and immune-stimulating complexes differ in their requirement for IL-12, indicating different pathways of action., Eur J Immunol, 29, 1774, 10.1002/(SICI)1521-4141(199906)29:06<1774::AID-IMMU1774>3.0.CO;2-1
C Czerkinsky, 2009, Enteric vaccines for the developing world: a challenge for mucosal immunology., Mucosal Immunol, 2, 284, 10.1038/mi.2009.22
LJ Hall, 2009, Characterisation of a live Salmonella vaccine stably expressing the Mycobacterium tuberculosis Ag85B-ESAT6 fusion protein., Vaccine, 27, 6894, 10.1016/j.vaccine.2009.09.007
E Casini, 1972, [Bacterial vaccines for oral administration and local mechanisms of immunity]., Ann Sclavo, 14, 547
S Liang, 2009, In vivo and in vitro adjuvant activities of the B subunit of Type IIb heat-labile enterotoxin (LT-IIb-B5) from Escherichia coli., Vaccine, 27, 4302, 10.1016/j.vaccine.2009.05.027
JD Boyer, 2005, DNA prime Listeria boost induces a cellular immune response to SIV antigens in the rhesus macaque model that is capable of limited suppression of SIV239 viral replication., Virology, 333, 88, 10.1016/j.virol.2004.12.026
G Perdigon, 1988, [Adjuvant activity of lactic bacteria: perspectives for its use in oral vaccines]., Rev Argent Microbiol, 20, 141
PH Pouwels, 1998, Lactic acid bacteria as antigen delivery vehicles for oral immunization purposes., Int J Food Microbiol, 41, 155, 10.1016/S0168-1605(98)00048-8
JM Wells, 2008, Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria., Nat Rev Microbiol, 6, 349, 10.1038/nrmicro1840
SN Tucker, 2008, Oral adenoviral-based vaccines: historical perspective and future opportunity., Expert Rev Vaccines, 7, 25, 10.1586/14760584.7.1.25
J Mestecky, 2008, Oral immunization: an update., Curr Opin Gastroenterol, 24, 713, 10.1097/MOG.0b013e32830d58be
J Fu, 2009, Enhancing efficacy and mucosa-tropic distribution of an oral HIV-PsV DNA vaccine in animal models., J Drug Target, 17, 803, 10.3109/10611860903089768
JF Ning, 2009, Oral delivery of DNA vaccine encoding VP28 against white spot syndrome virus in crayfish by attenuated Salmonella typhimurium., Vaccine, 27, 1127, 10.1016/j.vaccine.2008.11.075
SI Cazorla, 2008, Oral vaccination with Salmonella enterica as a cruzipain-DNA delivery system confers protective immunity against Trypanosoma cruzi., Infect Immun, 76, 324, 10.1128/IAI.01163-07
J Kindrachuk, 2008, Activation and regulation of toll-like receptor 9: CpGs and beyond., Mini Rev Med Chem, 8, 590, 10.2174/138955708784534481
A Forsman, 2003, Uptake of amplifiable fragments of retrotransposon DNA from the human alimentary tract., Mol Genet Genomics, 270, 362, 10.1007/s00438-003-0930-3
L Van Kaer, 1994, Altered peptidase and viral-specific T cell response in LMP2 mutant mice., Immunity, 1, 533, 10.1016/1074-7613(94)90043-4
RE Toes, 2001, Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products., J Exp Med, 194, 1, 10.1084/jem.194.1.1
IA York, 1999, Proteolysis and class I major histocompatibility complex antigen presentation., Immunol Rev, 172, 49, 10.1111/j.1600-065X.1999.tb01355.x
XY Mo, 1999, Distinct proteolytic processes generate the C and N termini of MHC class I-binding peptides., J Immunol, 163, 5851, 10.4049/jimmunol.163.11.5851
A Azizi, 2007, Viral peptide immunogens: current challenges and opportunities., J Pept Sci, 13, 776, 10.1002/psc.896
U Duesberg, 2002, Cell activation by synthetic lipopeptides of the hepatitis C virus (HCV) —core protein is mediated by toll like receptors (TLRs) 2 and 4., Immunol Lett, 84, 89, 10.1016/S0165-2478(02)00178-5
Y Yamashita, 2004, Role of the polypeptide region of a 33 kDa mycobacterial lipoprotein for efficient IL-12 production., Cell Immunol, 229, 13, 10.1016/j.cellimm.2004.06.001
NW Schroder, 2004, Lipopolysaccharide binding protein binds to triacylated and diacylated lipopeptides and mediates innate immune responses., J Immunol, 173, 2683, 10.4049/jimmunol.173.4.2683
DC Jackson, 2004, A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses., Proc Natl Acad Sci U S A, 101, 15440, 10.1073/pnas.0406740101
S Voss, 2007, The activity of lipopeptide TLR2 agonists critically depends on the presence of solubilizers., Eur J Immunol, 37, 3489, 10.1002/eji.200737537
Y Sumikawa, 2006, Induction of beta-defensin 3 in keratinocytes stimulated by bacterial lipopeptides through toll-like receptor 2., Microbes Infect, 8, 1513, 10.1016/j.micinf.2006.01.008
D Sirskyj, 2010, Innovative bioinformatic approaches for developing peptide-based vaccines against hypervariable viruses., Immunol Cell Biol
A Azizi, 2008, Induction of broad cross-subtype-specific HIV-1 immune responses by a novel multivalent HIV-1 peptide vaccine in cynomolgus macaques., J Immunol, 180, 2174, 10.4049/jimmunol.180.4.2174
JS Lambert, 2001, A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects., Vaccine, 19, 3033, 10.1016/S0264-410X(01)00051-2
CO Tacket, 2009, Plant-based oral vaccines: results of human trials., Curr Top Microbiol Immunol, 332, 103
SJ Streatfield, 2005, Delivery of plant-derived vaccines., Expert Opin Drug Deliv, 2, 719, 10.1517/17425247.2.4.719
SJ Streatfield, 2005, Plant-based vaccines for animal health., Rev Sci Tech, 24, 189
RW Hammond, 2009, Plant production of veterinary vaccines and therapeutics., Curr Top Microbiol Immunol, 332, 79
AM Walmsley, 2000, Plants for delivery of edible vaccines., Curr Opin Biotechnol, 11, 126, 10.1016/S0958-1669(00)00070-7
TA Haq, 1995, Oral immunization with a recombinant bacterial antigen produced in transgenic plants., Science, 268, 714, 10.1126/science.7732379
T Nochi, 2007, Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination., Proc Natl Acad Sci U S A, 104, 10986, 10.1073/pnas.0703766104
T Nochi, 2009, A rice-based oral cholera vaccine induces macaque-specific systemic neutralizing antibodies but does not influence pre-existing intestinal immunity., J Immunol, 183, 6538, 10.4049/jimmunol.0901480
M Amin, 2009, Impact of chitosan coating of anionic liposomes on clearance rate, mucosal and systemic immune responses following nasal administration in rabbits., Colloids Surf B Biointerfaces, 74, 225, 10.1016/j.colsurfb.2009.07.024
O Borges, 2007, Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles., Eur J Pharm Sci, 32, 278, 10.1016/j.ejps.2007.08.005
DE Katz, 2003, Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen., Vaccine, 21, 341, 10.1016/S0264-410X(02)00613-8
A Frey, 1996, Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting., J Exp Med, 184, 1045, 10.1084/jem.184.3.1045
JF Mann, 2009, Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection., Vaccine, 27, 3643, 10.1016/j.vaccine.2009.03.040
RL Owen, 1974, Epithelial cell specialization within human Peyer's patches: an ultrastructural study of intestinal lymphoid follicles., Gastroenterology, 66, 189, 10.1016/S0016-5085(74)80102-2
LJ Hathaway, 2000, The role of M cells in mucosal immunity., Cell Mol Life Sci, 57, 323, 10.1007/PL00000693
A Gebert, 2000, [The mechanisms of antigen uptake in the small and large intestines: the roll of the M cells for the initiation of immune responses]., Z Gastroenterol, 38, 855
EM Kuhn, 1996, Morphological characteristics of the ileal Peyer's patches in the rhesus macaque: a histological and ultrastructural study., Anat Histol Embryol, 25, 65, 10.1111/j.1439-0264.1996.tb00061.x
MA Clark, 1998, M-cell surface beta1 integrin expression and invasin-mediated targeting of Yersinia pseudotuberculosis to mouse Peyer's patch M cells., Infect Immun, 66, 1237, 10.1128/IAI.66.3.1237-1243.1998
A Gebert, 1999, M cells at locations outside the gut., Semin Immunol, 11, 165, 10.1006/smim.1999.0172
A Gebert, 1999, The development of M cells in Peyer's patches is restricted to specialized dome-associated crypts., Am J Pathol, 154, 1573, 10.1016/S0002-9440(10)65410-7
Y Yuki, 2009, Mucosal vaccines: novel advances in technology and delivery., Expert Rev Vaccines, 8, 1083, 10.1586/erv.09.61
DJ Brayden, 2005, Keynote review: intestinal Peyer's patch M cells and oral vaccine targeting., Drug Discov Today, 10, 1145, 10.1016/S1359-6446(05)03536-1
R Kuolee, 2008, M cell-targeted delivery of vaccines and therapeutics., Expert Opin Drug Deliv, 5, 693, 10.1517/17425247.5.6.693
HM Meynell, 1999, Up-regulation of microsphere transport across the follicle-associated epithelium of Peyer's patch by exposure to Streptococcus pneumoniae R36a., FASEB J, 13, 611, 10.1096/fasebj.13.6.611
P Tyrer, 2002, Validation and quantitation of an in vitro M-cell model., Biochem Biophys Res Commun, 299, 377, 10.1016/S0006-291X(02)02631-1
JF Mann, 2004, Optimisation of a lipid based oral delivery system containing A/Panama influenza haemagglutinin., Vaccine, 22, 2425, 10.1016/j.vaccine.2003.11.067
MY Chou, 2008, Oxidation-specific epitopes are important targets of innate immunity., J Intern Med, 263, 479, 10.1111/j.1365-2796.2008.01968.x
A Scibelli, 2005, Flavoridin inhibits Yersinia enterocolitica uptake into fibronectin-adherent HeLa cells., FEMS Microbiol Lett, 247, 51, 10.1016/j.femsle.2005.04.024
LH Saltman, 1996, A region of the Yersinia pseudotuberculosis invasin protein that contributes to high affinity binding to integrin receptors., J Biol Chem, 271, 23438, 10.1074/jbc.271.38.23438
B Sinha, 1999, Fibronectin-binding protein acts as Staphylococcus aureus invasin via fibronectin bridging to integrin alpha5beta1., Cell Microbiol, 1, 101, 10.1046/j.1462-5822.1999.00011.x
MH Jang, 2004, Intestinal villous M cells: an antigen entry site in the mucosal epithelium., Proc Natl Acad Sci U S A, 101, 6110, 10.1073/pnas.0400969101
PA Kozlowski, 2002, Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle., J Immunol, 169, 566, 10.4049/jimmunol.169.1.566
PN Gupta, 2007, M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B., J Drug Target, 15, 701, 10.1080/10611860701637982
EC Lavelle, 2000, Mucosal immunogenicity of plant lectins in mice., Immunology, 99, 30, 10.1046/j.1365-2567.2000.00932.x
X Wang, 2005, Transgene vaccination using Ulex europaeus agglutinin I (UEA-1) for targeted mucosal immunization against HIV-1 envelope., Vaccine, 23, 3836, 10.1016/j.vaccine.2005.02.023
M Manocha, 2005, Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target., Vaccine, 23, 5599, 10.1016/j.vaccine.2005.06.031
YT Chionh, 2009, M-cell targeting of whole killed bacteria induces protective immunity against gastrointestinal pathogens., Infect Immun, 77, 2962, 10.1128/IAI.01522-08
PJ Giannasca, 1999, Human intestinal M cells display the sialyl Lewis A antigen., Infect Immun, 67, 946, 10.1128/IAI.67.2.946-953.1999
S Kerneis, 1997, Conversion by Peyer's patch lymphocytes of human enterocytes into M cells that transport bacteria., Science, 277, 949, 10.1126/science.277.5328.949
LK Gram, 2009, Impact of carriers in oral absorption: Permeation across Caco-2 cells for the organic anions estrone-3-sulfate and glipizide., Eur J Pharm Sci, 37, 378, 10.1016/j.ejps.2009.03.008
JS Lim, 2009, Caveolae-mediated entry of Salmonella typhimurium in a human M-cell model., Biochem Biophys Res Commun, 390, 1322, 10.1016/j.bbrc.2009.10.145
E Gullberg, 2000, Expression of specific markers and particle transport in a new human intestinal M-cell model., Biochem Biophys Res Commun, 279, 808, 10.1006/bbrc.2000.4038
K Hase, 2009, Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response., Nature, 462, 226, 10.1038/nature08529
K Terahara, 2008, Comprehensive gene expression profiling of Peyer's patch M cells, villous M-like cells, and intestinal epithelial cells., J Immunol, 180, 7840, 10.4049/jimmunol.180.12.7840
S Langermann, 2000, Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli., J Infect Dis, 181, 774, 10.1086/315258
TV Poggio, 2006, Intranasal immunization with a recombinant truncated FimH adhesin adjuvanted with CpG oligodeoxynucleotides protects mice against uropathogenic Escherichia coli challenge., Can J Microbiol, 52, 1093, 10.1139/w06-065
J Bouckaert, 2005, Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin., Mol Microbiol, 55, 441, 10.1111/j.1365-2958.2004.04415.x
PJ Giannasca, 1999, Human intestinal M cells display the sialyl Lewis A antigen., Infect Immun, 67, 946, 10.1128/IAI.67.2.946-953.1999
S Misumi, 2009, : Targeted delivery of immunogen to primate m cells with tetragalloyl lysine dendrimer., J Immunol, 182, 6061, 10.4049/jimmunol.0802928